Patients with primary myelofibrosis who require treatment but present with a platelet count in the 50–100 × 10&sup9;/L range represent a distinct and challenging clinical subgroup. The presence of thrombocytopenia at this level has direct implications for how first-line therapy is selected and dosed.
This protocol addresses myelofibrosis that is active enough to warrant treatment, occurring in the specific setting of a platelet count between 50 and 100 × 10&sup9;/L — a degree of thrombocytopenia that constrains standard dosing approaches.
First-line management in this setting is guided by the platelet count and centres on a dose-adjusted targeted therapy strategy, with certain agents and combination approaches available depending on clinical context. The full protocol specifies agent selection, dosing adjustments, and the decision sequence — none of which should be applied without consulting the complete evidence-based regimen.